Is Bayer (BAYRY) Stock Outpacing Its Medical Peers This Year?
Werte in diesem Artikel
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Bayer Aktiengesellschaft (BAYRY) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bayer Aktiengesellschaft is one of 1011 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Bayer Aktiengesellschaft is currently sporting a Zacks Rank of #2 (Buy).The Zacks Consensus Estimate for BAYRY's full-year earnings has moved 5.3% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.Based on the latest available data, BAYRY has gained about 33.4% so far this year. In comparison, Medical companies have returned an average of 4.4%. This means that Bayer Aktiengesellschaft is outperforming the sector as a whole this year.Enhabit (EHAB) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 15.9%.In Enhabit's case, the consensus EPS estimate for the current year increased 32.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).Looking more specifically, Bayer Aktiengesellschaft belongs to the Large Cap Pharmaceuticals industry, which includes 12 individual stocks and currently sits at #69 in the Zacks Industry Rank. Stocks in this group have gained about 6.3% so far this year, so BAYRY is performing better this group in terms of year-to-date returns.On the other hand, Enhabit belongs to the Medical Services industry. This 59-stock industry is currently ranked #77. The industry has moved +5.2% year to date.Going forward, investors interested in Medical stocks should continue to pay close attention to Bayer Aktiengesellschaft and Enhabit as they could maintain their solid performance.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report Enhabit, Inc. (EHAB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf Bayer
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Bayer
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Bayer
Analysen zu Bayer
Datum | Rating | Analyst | |
---|---|---|---|
12:06 | Bayer Kaufen | DZ BANK | |
24.03.2025 | Bayer Neutral | Goldman Sachs Group Inc. | |
24.03.2025 | Bayer Neutral | JP Morgan Chase & Co. | |
20.03.2025 | Bayer Market-Perform | Bernstein Research | |
17.03.2025 | Bayer Neutral | JP Morgan Chase & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
12:06 | Bayer Kaufen | DZ BANK | |
27.11.2024 | Bayer Kaufen | DZ BANK | |
14.11.2024 | Bayer Kaufen | DZ BANK | |
06.08.2024 | Bayer Kaufen | DZ BANK | |
06.06.2024 | Bayer Kaufen | DZ BANK |
Datum | Rating | Analyst | |
---|---|---|---|
24.03.2025 | Bayer Neutral | Goldman Sachs Group Inc. | |
24.03.2025 | Bayer Neutral | JP Morgan Chase & Co. | |
20.03.2025 | Bayer Market-Perform | Bernstein Research | |
17.03.2025 | Bayer Neutral | JP Morgan Chase & Co. | |
11.03.2025 | Bayer Neutral | Goldman Sachs Group Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
31.10.2019 | Bayer Verkaufen | Independent Research GmbH | |
21.08.2019 | Bayer Verkaufen | Independent Research GmbH | |
01.08.2019 | Bayer Verkaufen | Independent Research GmbH | |
28.06.2019 | Bayer Verkaufen | Independent Research GmbH | |
25.04.2019 | Bayer Verkaufen | Independent Research GmbH |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Bayer nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen